About
vTv Therapeutics is a late-stage biopharmaceutical company developing oral small molecule drugs, including cadisegliatin, a liver-selective glucokinase activator in Phase 3 trials as a potential oral adjunctive therapy for type 1 diabetes.
Explore vTv Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.